Experience and consensus on stimulation of the anterior nucleus of thalamus for epilepsy. (26th October 2021)

• Record Type: Journal Article
• Authors: Fasano, Alfonso; Eliashiv, Dawn; Herman, Susan T.; Lundstrom, Brian N.; Polnerow, Dara; Henderson, Jaimie M.; Fisher, Robert S.
• Is Part Of: Epilepsia. Volume 62:issue 12(2021)
• Page Start: 2883
• Page End: 2898
• Publication Date: 2021-10-26
• Subjects: anterior thalamus -- consensus -- epilepsy -- neuromodulation -- neurostimulation -- seizure; Epilepsy -- Periodicals; 616.853
• DOI: 10.1111/epi.17094
• Languages: English
• ISSNs: 0013-9580

Abstract

Abstract: Deep brain stimulation of the anterior nuclei of thalamus (ANT‐DBS) is effective for reduction of seizures, but little evidence is available to guide practitioners in the practical use of this therapy. In an attempt to fill this gap, a questionnaire with 37 questions was circulated to 578 clinicians who were either engaged in clinical trials of or known users of DBS for epilepsy, with responses from 141, of whom 58.2% were epileptologists and 28.4% neurosurgeons. Multiple regions of the world were represented. The survey found that the best candidates for DBS were considered those with temporal or frontal seizures, refractory to at least two medicines. Motivations for renewing therapy upon battery depletion were reduced convulsive, impaired awareness, and severe seizures and improved quality of life. Targeting of leads mainly was by magnetic resonance imaging, sometimes with intraoperative imaging or microelectrode recording. The majority used transventricular approaches. Stimulation parameters mostly imitated the SANTE study parameters, except for initial stimulation amplitudes in the 2–3‐V or ‐mA range, versus 5 V in the SANTE study. Stimulation intensity was most often increased or reduced, respectively, for lack of efficacy or side effects, but changes in active contacts, cycle time, and pulse duration were also employed. Mood or memory problems or paresthesias were the side effects most responsible for adjustments. Off‐label sites stimulated included centromedian thalamus, hippocampus, neocortex, and a few others. Several physicians used DBS in conjunction with vagus nerve stimulation or responsive neurostimulation, although our study did not track efficacy for combined use. Experienced users varied more from published parameters than did inexperienced users. In conclusion, surveys of experts can provide Class IV evidence for the most prevalent practical use of ANT‐DBS. We present a flowchart for one protocol combining common practices. Controlled comparisons will be needed to choose the best approach.